Senior leadership and organizational depth across every discipline this work requires.
Our leadership team has led pharmaceutical R&D, regulatory, clinical and commercial programs. Introductions to the leadership team are available to qualified partners and investors under NDA.
Experience taking complex formulations from concept through process development, validation and technology transfer.
Experience in regulatory strategy, dossier preparation and agency interaction across the US, Europe, the UK and other markets.
Experience designing and running the clinical and bioequivalence programs that support differentiated products.
Experience in portfolio selection, partnering, licensing and commercial launch of specialty products.
Our R&D organization brings together experienced specialists in formulation and analytical development, project management, intellectual property, clinical research, developmental quality, and packaging.
Target and mechanism characterization at the molecular level, underpinning every formulation and development decision.
In-vivo and mechanistic pharmacology establishing performance and safety profiles ahead of clinical development.
Preclinical study design and execution to support regulatory filings and de-risk clinical progression.
Clinical strategy and execution aligned to each product's defined regulatory pathway.
Complex injectable, sterile, and advanced-delivery formulation design, paired with the analytical methods that validate it.
Quality oversight embedded from early development, not bolted on before filing.
Primary and secondary packaging development suited to complex, sensitive dosage forms.
Scale-up, technical transfer, and manufacturing quality oversight through clinical readiness.
Regulatory pathway planning and IP strategy for differentiated, defensible products.
Cross-functional coordination keeping programs moving through disciplined stage gates.
Market assessment, partner evaluation, and deal structuring for licensing and co-development.
Off Targets maintains ongoing access to a network of Key Opinion Leaders (KOLs) and subject matter experts (SMEs) who provide continuous scientific, clinical, and regulatory input throughout development — extending our internal capability with external expertise exactly when each program needs it.